Berlin Declaration: Biopharmaceutical Industry Vision for Equitable Access in Pandemics
The innovative biopharmaceutical industry, having developed COVID-19 vaccines and treatments at record speed and in historic quantities, proposes to create a collaborative solution for more equitable rollout of vaccines, treatments and diagnostics for future pandemics.
In particular, the innovative biopharmaceutical industry is willing to reserve an allocation of real-time production of vaccines, treatments and diagnostics for priority populations in lower income countries and take measures to make them available and affordable.
We call on other stakeholders to work together with industry to shape a future where everyone is better protected from the threat of pandemics. Tweet this
To be successful, we call on other stakeholders to work together with industry to help make this proposal a reality and shape a future where everyone is better protected from the threat of pandemics.
This Berlin Declaration draws on the lessons we have learned and sets out an approach for more equitable pandemic preparedness and response, based on commitments and contributions from a global collaboration of public, private and charitable sectors together with civil society. Critical for success is to ensure that pandemic VTDs reach those who need them most, no matter where they live, from the outset of future pandemics.
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents over 90 innovative pharmaceutical companies and associations across the globe. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community improve the lives of people everywhere. The industry’s two million employees discover, develop, and deliver medicines and vaccines that advance global health.Learn more
Media ContactAbigail Jones email@example.com